Safe prolonged use of brentuximab vedotin in a patient with Classical Hodgkin Lymphoma on hemodialysis

Abstract

Classical Hodgkin Lymphoma (cHL) is a B-cell derived lymphoma with excellent cure rates, however poor functional status or co-morbid conditions limit treatment options. Brentuximab vedotin (BV), a CD30 antibody drug conjugate, has an expanding role in cHL treatment. A 53-year-old man with multiple co-morbidities including end stage renal disease (ESRD) presenting with pancytopenia was found to have cHL. Not a candidate for intensive chemotherapy, he was safely maintained on intermittent BV for three years. Literature on prolonged BV use in hemodialysis is extremely limited. This case suggests BV as a safe treatment option for CD30 positive cHL in patients with ESRD on hemodialysis.

Keywords

• Classical Hodgkin Lymphoma
• Brentuximab vedotin
• ESRD
• Hemodialysis
• Pharmacology